New Search
If you are not happy with the results below please do another search
November 14, 2018
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN...
read more →
July 26, 2018
Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in...
read more →
April 26, 2018
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate,...
read more →
April 16, 2018
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate...
read more →
December 12, 2017
Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American...
read more →
October 11, 2017
Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has...
read more →
August 10, 2017
Will Rapidly Advance Promising Drug Candidates to the Clinic SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene...
read more →
September 7, 2016
SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene) for achievements in preclinical development...
read more →
November 18, 2015
SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ -- Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon Ceremony 2015 Presenting DiNA Awards. ...
read more →
October 23, 2014
Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014 – Sutro Biopharma...
read more →
Next Page »
